Amb motiu del tancament d'estiu, la validació de documents es reprendrà a partir del 28 d'agost de 2026. Disculpeu les molèsties.
Con motivo del cierre de verano, la validación de documentos se reanudará a partir del 28 de agosto de 2026. Disculpad las molestias
Due to the summer closure, document validation will resume starting August 28, 2026. We apologize for any inconvenience.

Files

529753.pdf (72.03 KB)

Document type

Article

Version

Published version

Publication date

2002-02-01

Publication license

cc-by-nc-sa (c) García del Muro Solans, Xavier et al., 2002
Please use this identifier to cite or link to this item: https://hdl.handle.net/2445/120701

Phase II multicentre study of docetaxel plus cisplatin in patients with advanced urothelial cancer

Journal Title

Authors

Director/Tutor

Journal ISSN

Volume Title

Related resource

https://doi.org/10.1038/sj.bjc.6600121

Abstract

A multicentre phase II trial was undertaken to evaluate the activity and toxicity of docetaxel plus cisplatin as first-line chemotherapy in patients with urothelial cancer. Thirty-eight patients with locally advanced or metastatic transitional-cell carcinoma of the bladder, renal pelvis or ureter received the combination of docetaxel 75 mg m−2 and cisplatin 75 mg m−2 on day 1 and repeated every 21 days, to a maximum of six cycles. The median delivered dose-intensity was 98% (range 79-102%) of the planned dose for both drugs. There were seven complete responses and 15 partial responses, for and overall response rate of 58% (95% CI, 41-74%). Responses were even seen in three patients with hepatic metastases. The median time to progression was 6.9 months, and the median overall survival was 10.4 months. Two patients who achieved CR status remain free of disease at 4 and 3 years respectively. Grade 3-4 granulocytopenia occurred in 27 patients, resulting in five episodes of febrile neutropenia. There was one toxic death in a patient with grade 4 granulocytopenia who developed acute abdomen. Grade 3-4 thrombocytopenia was rare (one patient). Other grade 3-4 toxicities observed were anaemia (three patients), vomiting (five patients), diarrhoea (four patients), peripheral neuropathy (two patients) and non-neutropenic infections (seven patients). Docetaxel plus cisplatin is an effective and well-tolerated regimen for the treatment of advanced urothelial cancer, and warrants further investigation.

Subject

Càncer de bufeta, Cisplatí, Quimioteràpia del càncer, Medicaments antineoplàstics, Malalts de càncer

Subject (English)

Bladder cancer, Cisplatin, Cancer chemotherapy, Antineoplastic agents, Cancer patients

Citation

Collections

Articles publicats en revistes (Ciències Clíniques)

Citation

GARCÍA DEL MURO SOLANS, Xavier, et al. Phase II multicentre study of docetaxel plus cisplatin in patients with advanced urothelial cancer. British Journal of Cancer. 2002. Vol. 86, num. 3, pags. 326-330. ISSN 0007-0920. [consulted: 18 of August of 2026]. Available at: https://hdl.handle.net/2445/120701

Export metadata

JSON - METS

Share record